{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.9","upperLimit":"63.8","value":"57.9"},{"groupId":"OG001","lowerLimit":"32.7","upperLimit":"44.4","value":"38.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"281"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by RECIST 1.1. ORR as assessed by blinded independent central review per RECIST 1.1 is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (\\~ 2 years) PLUS Investigator's choice of paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m\\^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles. Participants who received pembrolizumab 200 mg IV Day 1 of 21-day cycle for up to 2 years, but experienced disease progression, were eligible to receive a second course of pembrolizumab 200 mg IV Day 1 of 21-day cycle, at the investigator's discretion, for 17 cycles (\\~ 1 year additional).","id":"OG000","title":"Pembrolizumab + Chemotherapy Combo"},{"description":"Participants received normal saline as placebo by IV infusion prior to chemotherapy on Day 1 of 21-day cycle for up to 35 cycles (\\~ 2 years) PLUS Investigator's choice of paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m\\^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles. Participants with documented disease progression following placebo chemotherapy combo could switch-over to receive pembrolizumab for up to 35 cycles (\\~ 2 years). Eligible cross over participants who stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to 17 cycles (\\~ 1 year additional).","id":"OG001","title":"Placebo + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The Intent-To-Treat population consisted of all randomized participants, regardless of whether or not they received study treatment. Participants were included in the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 19 months","title":"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}